Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.66 |
| ▸ | HTR1A | P08908 | 3/20 | 0.57 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27189518 | 0.87 | HTR2A (0.67) | HTR2AHTR1ATRPM8HTR1DHTR2C | |
| SCHEMBL27189554 | 0.86 | HTR2A (0.64) | HTR2AHTR1ATRPM8HTR1DHTR2C | |
| SCHEMBL27189559 | 0.86 | HTR2A (0.66) | HTR2AHTR1ATRPM8HTR1DHTR2C | |
| SCHEMBL27189585 | 0.86 | HTR2A (0.66) | HTR2AHTR1ATRPM8HTR1DHTR2C | |
| SCHEMBL13480312 | 0.85 | LTA4H (0.62) | HTR2AHTR1ATRPM8HTR1DLTA4H | |
| SCHEMBL4395931 | 0.84 | HTR2A (0.57) | HTR2AHTR1ATRPM8HTR1DHTR2C | |
| SCHEMBL31708211 | 0.84 | HTR2A (0.48) | HTR2AHTR1ATRPM8LTA4HPLA2G2A | |
| SCHEMBL27189549 | 0.83 | HTR2A (0.62) | HTR2AHTR1ATRPM8HTR1DLTA4H | |
| SCHEMBL30712097 | 0.83 | HTR2A (0.47) | HTR2AHTR1ATRPM8HTR1DLTA4H | |
| SCHEMBL27189566 | 0.82 | HTR2A (0.61) | HTR2AHTR1ATRPM8HTR1DHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-8912220-B2 | Compounds and methods of use thereof | Galenea Pharmaceuticals | 2014-12-16 | — | — | US | disclosed |
| US-8912220-B2 | Compounds and methods of use thereof | Galenea Pharmaceuticals | 2014-12-16 | — | — | US | disclosed |
| EP-2464227-A1 | COMPOUNDS AND METHODS OF USE THEREOF | Galenea Corporation (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | disclosed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | disclosed |
| WO-2011019738-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | HTR2A 34/4885HTR1A 38/4885TRPM8 2766/4885 |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | HTR2A 34/4885HTR1A 38/4885TRPM8 2766/4885 |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | HTR2A 34/4885HTR1A 38/4885TRPM8 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.